Drug intelligence / Profile preview

HDT-331

Development stage: Unknown
Lead developer: HDT Bio
Modality: Small Molecules, mRNA Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

HDT-331 is a self-amplifying RNA (saRNA) vaccine candidate developed by HDT Bio in collaboration with the University of Texas Medical Branch. It is designed to provide immunization against Nipah virus (NiV), a highly pathogenic zoonotic virus with pandemic potential. The vaccine utilizes the proprietary LION™ delivery system, which stabilizes and transports the saRNA into cells, where it amplifies and expresses viral antigens to stimulate an immune response. The primary mechanism of action is immunostimulation, aiming to induce both humoral and cellular immunity against Nipah virus infection. As of late 2022, development was at the research/preclinical stage[1][2][4][8].

Other names: HDT 331HDT331HDT-331

Beyond the preview

Go deeper on HDT-331.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HDT-331.

Explore the full profile